Imutex
London
About Imutex
Imutex Limited, formed in 2016, is a joint venture between SEEK Group and hVIVO plc to accelerate the development of a Broad-Spectrum Influenza Vaccine (BIV) and a Zika Vaccine. The development of BIV and Zika vaccines are key public health priorities identified by the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) in the United States.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $20.5M
- Funding stage: Seed
- Last round: Seed (Apr 2016)
- Website: imutex.com
- Phone: +44 207 036 8550
Industries & Categories
Biotechnology, Health Care, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/imutex-140952 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.